Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

780
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
780
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

976
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
976
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.3K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.3K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

864
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
864
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.4K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethnopharmacological Validation of Selected <i>Coleus</i> and <i>Plectranthus</i> spp. For Skin-Related Applications Through In Vitro Biological Assays.

Plants (Basel, Switzerland)·2026
Same author

Genomics in Nursing Curricula: A Qualitative Study of Portuguese Educators' Views.

International nursing review·2026
Same author

When Pancreatitis Strikes the Colon: A Rare Case Report of Sigmoid Perforation.

GE Portuguese journal of gastroenterology·2026
Same author

Beyond Biopsy: Real-World Evaluation of the Fibrosis-6 Score in a Portuguese Cohort.

GE Portuguese journal of gastroenterology·2026
Same author

In vitro evaluation of candidate probiotic bacteria against enterotoxigenic Escherichia coli (ETEC) isolated from post-weaning diarrhea in piglets.

Microbial pathogenesis·2026
Same author

Sealing the gap: a hybrid stitch approach to gastrostomy closure.

VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy·2026

Related Experiment Video

Updated: Mar 2, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

13.0K

Early Intervention Prevents Disease Progression in Ulcerative Colitis: A Multicenter Retrospective Study.

Joana Camões Neves1, Tiago Leal1, Samuel Fernandes2

  • 1Gastroenterology Department, Unidade Local de Saúde Braga, Braga, Portugal.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|February 28, 2026
PubMed
Summary

Early biologic therapy (BT) for ulcerative colitis (UC) may prevent long-term disease progression. This study suggests initiating BT within 12 months of diagnosis improves outcomes and reduces structural damage.

Keywords:
Disease ProgressionEarly Biologic TherapyUlcerative ColitisWindow of Opportunity

More Related Videos

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.7K
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.8K

Related Experiment Videos

Last Updated: Mar 2, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

13.0K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.7K
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.8K

Area of Science:

  • Gastroenterology
  • Immunology
  • Clinical Medicine

Background:

  • Ulcerative colitis (UC) is increasingly recognized as a progressive condition.
  • Unlike Crohn's disease, early biologic therapy (BT) benefits in UC are not well-established.
  • Disease progression in UC requires further evaluation to guide treatment strategies.

Purpose of the Study:

  • To assess the impact of early intervention on ulcerative colitis (UC) outcomes.
  • To determine if early biologic therapy (BT) initiation prevents disease progression.
  • To evaluate the long-term effects of early BT on UC structural and clinical endpoints.

Main Methods:

  • Retrospective multicenter study of adult UC patients with ≥5 years follow-up.
  • Early intervention defined as BT initiation within ≤12 months of diagnosis.
  • Primary outcome: UC progression (proximal extension, structural changes, dysplasia/cancer). Secondary outcomes: hospitalizations, surgery, corticosteroid use.

Main Results:

  • Late BT initiation independently predicted composite UC progression (HR 4.39, p=0.005).
  • Early BT reduced proximal disease extension (28.6% vs 0.0%, p=0.001).
  • Late BT predicted colonic structural damage (HR 4.83, p=0.033); no clinical outcome differences observed.

Conclusions:

  • Early initiation of biologic therapy (BT) may mitigate long-term disease progression in ulcerative colitis (UC).
  • A critical window of opportunity exists for early intervention in UC management.
  • Findings support considering early BT to alter the progressive course of UC.